Nasopax Uno Kamilla (Oxymetazoline Hydrochloride)

Oxymetazoline hydrochloride, the active ingredient in Nasopax Uno Kamilla, is an alpha‑adrenergic agonist presented as a nasal spray for endosinusial use. It provides temporary relief of nasal congestion caused by colds, allergies, and sinusitis in adults and older children. GNH USA supplies Nasopax Uno Kamilla as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Oxymetazoline acts on the nasal vasculature to relieve congestion in several common conditions.

- Nasal congestion: reduces swelling of nasal mucosa for rapid airway opening. - Allergic rhinitis: alleviates blockage associated with seasonal or perennial allergies. - Acute sinusitis: eases sinus pressure by clearing nasal passages.

Oxymetazoline nasal spray may cause a range of adverse reactions.

Common Side Effects: - Nasal irritation or burning sensation. - Dryness of the nasal passages. - Sneezing shortly after application. - Mild headache. - Transient epistaxis (nosebleed). - Unpleasant taste.

Serious or Rare Side Effects: - Elevated blood pressure or hypertension. - Rapid heart rate (tachycardia) or arrhythmias. - Severe nasal ulceration or tissue necrosis. - Rebound nasal congestion (rhinitis medicamentosa) with prolonged use. - Cardiovascular chest pain. - Allergic reactions such as rash or swelling.

Before using Nasopax Uno Kamilla, consider the following safety measures.

- Pregnancy: consult a healthcare professional before use. - Breastfeeding: use only if the benefit outweighs potential risk. - Age restrictions: not recommended for children under 6 years. - Duration of use: limit to no more than three consecutive days to avoid rebound congestion. - Drug interactions: inform the prescriber of any concurrent antihypertensive or MAO‑inhibitor therapy. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Oxymetazoline may interact with several medication classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Tricyclic antidepressants: additive vasoconstrictive effects.

Moderate Interactions (Monitor Closely): - Beta‑blockers: possible enhancement of blood‑pressure changes. - Antihypertensive agents: monitor blood pressure for additive effects. - Other nasal decongestants: increased risk of excessive vasoconstriction.